-
Norwegian company Algeta ASA, in a
partnership with Bayer,
under the
trade name
Xofigo (formerly Alpharadin), and is
distributed as a
solution containing radium-223...
- alpha-particle
emitting radiopharmaceuticals. The lead
product of the company,
Xofigo is the
first marketed alpha-particle
emitting radiopharmaceutics for cancer...
-
radiation drug
Xofigo from Bayer, Algeta".
Archived from the
original on 28 June 2013.
Retrieved 1
October 2014. "FDA
approves Xofigo for
advanced prostate...
- treatment. Radium-223
dichloride (USP,
radium chloride Ra 223),
tradename Xofigo (formerly Alpharadin), is an alpha-emitting radiopharmaceutical.
Bayer received...
-
cells expressing PSMA, but
Xofigo attacks all bone metastases.
Qualified patients are 30% less
likely to die when
treated by
Xofigo than if
treated by a placebo...
- were
Xarelto (rivaroxaban),
Eylea (aflibercept),
Stivarga (regorafenib),
Xofigo (radium-223), and
Adempas (riociguat).: 93 Top-selling
products as of 2014...
- med-tech
products to the market. Many of
these products, such as Firazyr®,
Xofigo®, Tracleer®, are
breakthrough therapies addressing life-threatening diseases...
- (INN)
xinomiline (INN)
xipamide (INN)
Xipere xipranolol (INN)
Xiral Xocova Xofigo Xofluza Xolair Xolegel Xolremdi Xopenex Hfa
Xopenex xorphanol (INN) Xospata...
-
therapy in
patients with hormone-refractory
metastatic prostate cancer.
Xofigo is a new alpha-emitting
pharmaceutical targeting bone metastasis. Phase...
